Related Experiment Video
Updated: Jun 22, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Peroxiporins in Triple-Negative Breast Cancer: Biomarker Potential and Therapeutic Perspectives
Anita Bijelić1, Tajana Silovski2,3, Monika Mlinarić4
1Department of Biology, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
Abstract:
Triple-negative breast cancer (TNBC) remains one of the most challenging subtypes since it is initially characterized by the absence of specific biomarkers and corresponding targeted therapies. Advances in methodology, translational informatics, genomics, and proteomics have significantly contributed to the identification of therapeutic targets. The development of innovative treatments, such as antibody-drug conjugates and immune checkpoint inhibitors, alongside chemotherapy, has now become the standard of care. However, the quest for biomarkers defining therapy outcomes is still ongoing. Peroxiporins, which comprise a subgroup of aquaporins, which are membrane pores facilitating the transport of water, glycerol, and hydrogen peroxide, have emerged as potential biomarkers for therapy response. Research on peroxiporins reveals their involvement beyond traditional channeling activities, which is also reflected in their cellular localization and roles in cellular signaling pathways. This research on peroxiporins provides fresh insights into the mechanisms of therapy resistance in tumors, offering potential avenues for predicting treatment outcomes and tailoring successful TNBC therapies.
Insights
Triple-negative breast cancer (TNBC) lacks targeted therapies. Peroxiporins show promise as biomarkers to predict treatment response and overcome therapy resistance in TNBC.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Triple-negative breast cancer (TNBC) presents a significant therapeutic challenge due to the absence of specific biomarkers and targeted treatments.
- Recent advancements in informatics, genomics, and proteomics have identified potential therapeutic targets for TNBC.
- Current standard care involves chemotherapy combined with novel treatments like antibody-drug conjugates and immune checkpoint inhibitors, yet biomarker discovery for therapy response remains critical.
Purpose of the Study:
- To explore the potential of peroxiporins as biomarkers for predicting therapy response in triple-negative breast cancer.
- To investigate the role of peroxiporins in cellular signaling and their implications for therapy resistance mechanisms in TNBC.
Main Methods:
- Review of existing research on peroxiporins, aquaporins, and their functions.
- Analysis of peroxiporin involvement in cellular localization and signaling pathways.
- Exploration of peroxiporins' potential as predictive biomarkers for TNBC treatment outcomes.
Main Results:
- Peroxiporins, a subgroup of aquaporins, facilitate the transport of water, glycerol, and hydrogen peroxide.
- Peroxiporins exhibit functions beyond simple channeling, influencing cellular localization and signaling pathways.
- Emerging research suggests peroxiporins as potential biomarkers for therapy response in TNBC.
Conclusions:
- Peroxiporins offer novel insights into the mechanisms underlying tumor therapy resistance.
- Identifying peroxiporins' roles may lead to improved prediction of treatment outcomes for TNBC.
- Targeting peroxiporins or utilizing them as biomarkers could pave the way for tailored and effective TNBC therapies.
Related Concept Videos
01:24Peroxisomes
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...